Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Mackey

Showing results (401-410 of 411) with videos related to

Pageof 42
Sort By:
Clinical Breast Cancer|October 11, 2015
A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast CancerMichael B Sawyer, Edith Pituskin, Sambasivarao Damaraju, et al.
BMJ Open|September 19, 2019
Comparing docosahexaenoic acid (DHA) concomitant with neoadjuvant chemotherapy versus neoadjuvant chemotherapy alone in the treatment of breast cancer (DHA WIN): protocol of a double-blind, phase II, randomised controlled trialMarnie Newell, John R Mackey, Gilbert Bigras, et al.
Breast Cancer Research and Treatment|April 13, 2023
Associations between health-related fitness and quality of life in newly diagnosed breast cancer patientsKerry S Courneya, Ki-Yong An, Fernanda Z Arthuso, et al.
Gastroenterology|June 19, 2012
Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinomaRaphaël Maréchal, Jean-Baptiste Bachet, John R Mackey, et al.
The Lancet. Oncology|March 25, 2011
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled studyMiguel Martin, Henri Roche, Tamas Pinter, et al.
Cancers|November 27, 2021
hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNAKaren Aughton, Nils O Elander, Anthony Evans, et al.
The Lancet. Oncology|December 19, 2012
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trialJohn R Mackey, Miguel Martin, Tadeusz Pienkowski, et al.
British Journal of Cancer|March 11, 2018
Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapyN O Elander, K Aughton, P Ghaneh, et al.
JAMA|May 24, 2022
Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical TrialPamela J Goodwin, Bingshu E Chen, Karen A Gelmon, et al.
British Journal of Cancer|March 9, 2018
Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancerN O Elander, K Aughton, P Ghaneh, et al.
Pageof 42

Showing results (401-410 of 411) with videos related to

Sort By:
Pageof 42
Clinical Breast Cancer|October 11, 2015
A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast CancerMichael B Sawyer, Edith Pituskin, Sambasivarao Damaraju, et al.
BMJ Open|September 19, 2019
Comparing docosahexaenoic acid (DHA) concomitant with neoadjuvant chemotherapy versus neoadjuvant chemotherapy alone in the treatment of breast cancer (DHA WIN): protocol of a double-blind, phase II, randomised controlled trialMarnie Newell, John R Mackey, Gilbert Bigras, et al.
Breast Cancer Research and Treatment|April 13, 2023
Associations between health-related fitness and quality of life in newly diagnosed breast cancer patientsKerry S Courneya, Ki-Yong An, Fernanda Z Arthuso, et al.
Gastroenterology|June 19, 2012
Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinomaRaphaël Maréchal, Jean-Baptiste Bachet, John R Mackey, et al.
The Lancet. Oncology|March 25, 2011
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled studyMiguel Martin, Henri Roche, Tamas Pinter, et al.
Cancers|November 27, 2021
hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNAKaren Aughton, Nils O Elander, Anthony Evans, et al.
The Lancet. Oncology|December 19, 2012
Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trialJohn R Mackey, Miguel Martin, Tadeusz Pienkowski, et al.
British Journal of Cancer|March 11, 2018
Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapyN O Elander, K Aughton, P Ghaneh, et al.
JAMA|May 24, 2022
Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical TrialPamela J Goodwin, Bingshu E Chen, Karen A Gelmon, et al.
British Journal of Cancer|March 9, 2018
Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancerN O Elander, K Aughton, P Ghaneh, et al.
Pageof 42